Retlirafusp alfa with apatinib and paclitaxel for stomach cancer
Part of Cancer, Digestive system clinical trials.
This trial tests a combination of three drugs to treat stomach or junction cancer that has spread or come back after initial immunotherapy treatment. The goal is to see if this combination can shrink tumors and help patients live longer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have stomach cancer or cancer where the stomach meets the esophagus that is advanced, unresectable, or has spread
- Your cancer is HER2 negative (a protein marker on the cancer cells)
- You tried immunotherapy as your first treatment and it did not work well enough
- Your blood counts, liver, kidney, and heart function are adequate
- You are 18 years or older and able to care for yourself with minimal assistance
- You have never taken a VEGFR inhibitor drug before (like apatinib, sorafenib, or sunitinib)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new immunotherapy drug (Retlirafusp Alfa) combined with chemotherapy before surgery for stomach or gastroesophageal junction cancer. It aims to shrink the tumor enough to allow surgery, and is for patients with specific types of HER2-negative or low-HER2 cancer and a PD-L1 CPS score of 1 or higher.
This study tests a new combination of drugs (apatinib, nab-paclitaxel, and possibly adebrelimab) for advanced stomach or gastroesophageal junction cancer that has progressed after initial treatment. The goal is to see if this combination can help control the cancer.
This trial tests a new drug combination (retlirafusp alfa plus chemotherapy) against a standard immunotherapy (PD-1 inhibitor) plus chemotherapy for people with advanced stomach or gastroesophageal junction cancer that has spread to the liver and who haven't had prior treatment for advanced disease.
This trial tests a new drug called retlirafusp alfa combined with chemotherapy as a treatment before and after surgery for a specific type of stomach cancer. It aims to see if this combination is safe and effective for patients whose cancer has a high level of a certain protein (CPS > 5) and is not driven by HER2.
This trial studies whether combining camrelizumab (an immunotherapy) and apatinib (a targeted pill) can control advanced, unresectable stomach or gastroesophageal junction cancer that has grown after first treatment. It also looks at how safe the combination is.
This study tests a combination of two drugs (paclitaxel, a chemotherapy, and apatinib, a targeted drug) with an immunotherapy (adebrelimab) for advanced stomach cancer. It may be an option if you've already tried immunotherapy and need a new approach.
Hear when a new Gastric Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.